FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for XALKORI (crizotinib) filed by Pfizer, authorizing a change or addition to the drug’s labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

SUPPL AP for XALKORI (CRIZOTINIB)